67Ga-citrate and 99Tcm-MDP for estimating the severity of vertebral osteomyelitis.
The aim of this study was to evaluate the roles of 67Ga-citrate and 99Tcm-methylene diphosphonate (99Tcm-MDP) planar and single photon emission tomographic (SPET) imaging in patients with vertebral osteomyelitis. Thirty patients (22 females, 8 males) aged 62.7 +/- 16.4 years (mean +/- s) were enrolled prospectively between May 1995 and May 1998. The patients had been on antibiotics for 7 +/- 4 weeks prior to the study. Histology was available for all but nine patients with mild infections, who were evaluated by a combination of magnetic resonance imaging (MRI), clinical and laboratory tests. 67Ga-citrate (185 MBq) and three-phase bone (555 MBq 99Tcm-MDP) planar and SPET imaging were performed in all patients, together with MRI as a comparison. In total, 67 infectious foci were detected. Based on histology, there were four cases of severe, 13 cases of moderate and four cases of mild osteomyelitis; nine mild infections were also classified by the combination of MRI, clinical and laboratory results. Combined MRI and 67Ga-citrate SPET correctly classified all patients; MRI detected all 67 infectious foci, whereas 67Ga-citrate SPET identified 54 only. False-negative results were seen with all other modalities, especially in cases of mild and moderate infection. 67Ga-citrate SPET identified unsuspected cases of endocarditis (n = 2), paravertebral abscess (n = 1), subaxillary soft tissue abscess (n = 1) and rib osteomyelitis (n = 1). For 67Ga-citrate SPET, the target-to-background ratio was 2.24 +/- 0.31, 1.76 +/- 0.07 and 1.30 +/- 0.18 for severe, moderate and mild osteomyelitis, respectively. Significant differences were noted between severe and moderate infection (P = 0.0051) and between severe and mild infection (P < 0.0001); that between moderate and mild infection was non-significant. For 99Tcm-MDP planar and SPET imaging, and for planar 67Ga-citrate imaging, there was no correlation with severity. We conclude that 67Ga-citrate SPET is able to identify vertebral osteomyelitis and detect additional sites of infection. It can also aid in determining the severity of infection and, potentially, the response to therapy.
Gratz
S
S
Department of Nuclear Medicine, Georg-August-University, Göttingen, Germany. sgratz@med.uni-goettingen.de
Dörner
J
J
Oestmann
J W
JW
Opitz
M
M
Behr
T
T
Meller
J
J
Grabbe
E
E
Becker
W
W
D000368:Aged; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D002951:Citrates; D005260:Female; D005708:Gallium; D005710:Gallium Radioisotopes; D006801:Humans; D007958:Leukocyte Count; D008279:Magnetic Resonance Imaging; D008297:Male; D010019:Osteomyelitis / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013131:Spine / Q000000981:diagnostic imaging* / Q000473:pathology; D013669:Technetium Tc 99m Medronate
D002951:Citrates; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D002097:C-Reactive Protein; D005708:Gallium; C103850:gallium citrate; D013669:Technetium Tc 99m Medronate